Breast implant "opt-out" order will detail BMS/Baxter/3M settlement.
This article was originally published in The Gray Sheet
Executive Summary
BREAST IMPLANT SETTLEMENT "OPT-OUT" ORDER, SLATED FOR JUDGE'S SIGNATURE either on Saturday, Oct. 7 or the week of Oct. 9, will advise Bristol-Myers Squibb, Baxter and 3M implant recipients of their options under a new agreement announced Oct. 2 by the U.S. District Court of Alabama. The technical purpose of the order from Judge Samuel Pointer, who is overseeing the class action settlement of breast implant product liability claims, is to free the 440,000 plaintiffs registered for the failed $4.23 bil. "global" class action settlement to pursue individual claims against manufacturers.